Latest Thesis
Viatris: the generics cash engine has to outrun the impairment overhang
Viatris reported 2025 revenue of $14.30 billion and Q1 2026 revenue of $3.52 billion. The thesis depends on durable generic-drug cash flow, portfolio pruning, debt reduction, regulatory execution and proof that recent losses are not masking a weakening franchise.
Financials and workspace tools are for paid members.
Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.
Recent Reports
Compact report index for this company.
ReportTypeUpdatedReadActions
Viatris: the generics cash engine has to outrun the impairment overhangViatris reported 2025 revenue of $14.30 billion and Q1 2026 revenue of $3.52 billion. The thesis depends on durable generic-drug cash flow, portfolio pruning, debt reduction, regulatory execution and proof that recent losses are not masking a weakening franchise.NASDAQMay 20, 2026Research reportReadSlides